Leukaemia Section
Mini Review

Classification of B-cell non-Hodgkin lymphomas (NHL)

Antonio Cuneo

Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy (AC)

Published in Atlas Database: February 2000
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/BNHLClassifID2067.html
DOI: 10.4267/2042/37588

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2000 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Note: B-cell NHL include a number of clinicopathologic subsets of lymphoid neoplasms having heterogeneous features. This situation is reflected by variations in the classification systems that were proposed over the last decade. Cytogenetic findings were recognized to help defining a rationale biologic ground for the nosologic classification of lymphomas.

An outlook of the salient cytogenetic entities in this spectrum of disorders is presented herein; a complete illustration of the cytogenetic profile of each disease is provided in specific cards. Unless otherwise specified the WHO classification system will be used.

Legend for immunophenotypes (below): +: positive in >90% of the cases; +/-: positive in more than 50% of the cases; -/+: positive in less than 50% of cases; -: positive in <10% of the cases; pan-B markers include CD19; CD20; CD79a; R = rearranged; sIg: surface immunoglobulins; cyIg: cytoplasmic Ig; IgV genes: genes encoding for the variable portion of the Ig.

Clinics and pathology

Disease

Small lymphocytic lymphoma (SLL)

Phenotype/cell stem origin

Histologic subset and Immunophenotype: Pan-B+; CD5+; CD23+; CD10-; sIgM+ faint.

Putative cell of origin: CD5+ virgin B-cell with germline IgV genes (as was recently demonstrated to be the case with chronic lymphocytic leukemia, the leukemic counterpart of SLL, it is likely that part of the cases may derive from post-germinal centre quiescent B-cells that harbour hypermutated IgV genes).

Clinics

Indolent disease; Leukemic involvement by lymphoid cells, including prolymphocytes and/or paraimmunoblasts Splenomegaly.

Cytogenetics
del(6)(q21-23) (20-30% of the cases).

Disease

Lymphoplasmacytic lymphoma

Phenotype/cell stem origin

Histologic subset and Immunophenotype: Pan-B+; CD5--; CD10--; cyIgM+.

Putative cell of origin: Peripheral B-lymphocyte transforming into plasma cell with mutated IgV genes and ongoing mutations.

Clinics

Indolent low-grade disease, with possible clinical and/or histologic progression.

Cytogenetics
t(9;14)(p13;q32) PAX5/IgH (50% of cases).

Disease

Follicle centre cell lymphoma

Phenotype/cell stem origin

Histologic subset and Immunophenotype: Pan-B+; CD10+/--; CD5--; sIg+. Putative cell of origin: Centrocytes / centroblasts of germinal centre origin with somatic hypermutation of the IgV genes and ongoing mutations (antigen driven stimulation).
**Classification of B-cell non-Hodgkin lymphomas (NHL)**

Cuneo A

Atlas Genet Cytogenet Oncol Haematol. 2000; 4(1)

**Clinics**
Indolent. Advanced stages predominate. Conflicting data as to the prognostic significance of the t(14;18)/BCL2.

**Cytogenetics**
t(14;18)(q32;q21) / BCL2 Rearr (70-80% of cases).

**Disease**
Diffuse large cell lymphoma

**Phenotype/cell stem origin**
Histologic subset and Immunophenotype: CD19+; CD22+; CD10-/+; Slg+.
Putative cell of origin: Large transformed B-cells harbouring somatic hypermutation of the Ig genes (ongoing mutations in some cases).

**Clinics**
Usually aggressive. Immunoblastic lymphoma (Kiel classification) do worse than centroblastic lymphomas. No convincing demonstration that any "primary" cytogenetic / molecular defect has prognostic significance; complex karyotype confers a shorter survival.

**Cytogenetics**
t(14;18) and p53 mutations (20% of the cases).
t(3;V)(q27;V)/ BCL6 Rearr (6-30% of cases (% variations depending on detection methods: molecular genetics and FISH more sensitive that conventional cytogenetics)).
Or variants c-MYC Rearr (7-10% of cases).

**Disease**
Burkitt’s lymphoma

**Phenotype/cell stem origin**
Histologic subset and Immunophenotype: Pan-B+; TdT-; CD10+; CD5-; sIgM+.
Putative cell of origin: Peripheral B-cells that have encountered the antigen and harbours somatic hypermutation of the Ig genes.

**Clinics**
Extremely aggressive disease. Specific treatment mandatory.

**Cytogenetics**
Or variants / c-MYC Rearr (80% of the cases).

**Disease**
Burkitt-like lymphoma

**Phenotype/cell stem origin**
Histologic subset and Immunophenotype: Pan-B+; TdT-; CD10+/CD5-; sIg+. Putative cell of origin: Peripheral B-cells that have encountered the antigen.

**Clinics**
Agressive disease.

**Cytogenetics**
Or variants / c-MYC Rearr (80% of the cases).

**Disease**
Mantle cell lymphoma

**Phenotype/cell stem origin**
Histologic subset and Immunophenotype: Pan-B+; CD5+; CD23-; CD10-/+; sIgM+ bright.
Putative cell of origin: CD5+ B-cells of the follicle mantle having germ line IgV gene sequences.

**Clinics**
Advanced stages predominate. Response to chemotherapy often unsatisfactory. Short survival. Complex karyotype carries an unfavourable prognostic significance.

**Cytogenetics**
t(11;14)(q13;q32)/BCL1 Rearr (50-90%) (molecular genetic methods have limited application due to variability of breakpoints; FISH is the most sensitive technique).

**Disease**
Marginal zone B-cell lymphoma (MZBCL)

**Phenotype/cell stem origin**
Histologic subset and Immunophenotype: Pan-B+; CD5-; CD23-; CD10+/CD11c+; cyIg+ (40% of the cells), sIgM+ bright; sIgD-.
Putative cell of origin: Marginal zone lymphocytes harbouring hypermutated IgV genes.

**Cytogenetics**
t(11;18)(q21;q21) P12/MLT fusion (30-50% of the low-grade MALT): Extra-nodal low-grade MALT lymphoma; indolent disease.
t(1;14)(p13;q32): Extra-nodal MALT lymphoma.
del(7)(q22-31) (40% of the cases): Splenic MZBCL. +3/+3q (30-70% of the cases): Nodal, extra-nodal and splenic MZBCL.

**References**


Kramer MH, Hermans J, Wijburg E, Philippe K, Geelen E, van Krieken JH, de Jong D, Maartense E, Schuuring E, Kluin PM. Clinical relevance of BCL2, BCL6, and MYC rearrangements in Cases with dual 8;14 and 14;18 translocations have a worse outcome (data requiring confirmation -1 study only).

**Cytogenetics**
t(8;14) or variants (25% of cases).
t(8;14)+ t(14;18) (30% of cases).

**Disease**
Mantle cell lymphoma

**Phenotype/cell stem origin**
Histologic subset and Immunophenotype: Pan-B+; CD5+; CD23-; CD10-/+; sIgM+ bright.
Putative cell of origin: CD5+ B-cells of the follicle mantle having germ line IgV gene sequences.

**Clinics**
Advanced stages predominate. Response to chemotherapy often unsatisfactory. Short survival. Complex karyotype carries an unfavourable prognostic significance.

**Cytogenetics**
t(11;14)(q13;q32)/BCL1 Rearr (50-90%) (molecular genetic methods have limited application due to variability of breakpoints; FISH is the most sensitive technique).

**Disease**
Marginal zone B-cell lymphoma (MZBCL)

**Phenotype/cell stem origin**
Histologic subset and Immunophenotype: Pan-B+; CD5-; CD23-; CD10+/CD11c+; cyIg+ (40% of the cells), sIgM+ bright; sIgD-.
Putative cell of origin: Marginal zone lymphocytes harbouring hypermutated IgV genes.

**Cytogenetics**
t(11;18)(q21;q21) P12/MLT fusion (30-50% of the low-grade MALT): Extra-nodal low-grade MALT lymphoma; indolent disease.
t(1;14)(p13;q32): Extra-nodal MALT lymphoma.
del(7)(q22-31) (40% of the cases): Splenic MZBCL. +3/+3q (30-70% of the cases): Nodal, extra-nodal and splenic MZBCL.


This article should be referenced as such: